Abstract:

Objective To explore the association of oxcarbazepine（OXC）⁃ induced cutaneous adverse reactions（CARs）with HLA ⁃B*1502 and HLA ⁃B*1301 genes. Methods A multicenter case ⁃control study was performed. Patients with OXC ⁃induced CARs，OXC ⁃tolerant patients，and healthy controls were recruited from January 2017 to December 2020. DNAs were extracted from peripheral blood. The genotype of HLA⁃B was detected by polymerase chain reaction（PCR）and Sanger sequencing. Chi⁃square test and Fisher′s exact test were used to compare the differences in the rate of HLA⁃B*1502 and HLA⁃B*1301 alleles between OXC⁃induced CARs group and OXC⁃tolerant group or normal control group. Results 15 patients with OXC⁃induced CARs，64 OXC⁃tolerant patients，and 100 healthy individuals were included in this study. One patient with OXC⁃induced SJS/TEN carried HLA⁃B*1502 gene. The rate of HLA⁃B *1502 gene in mild OXC⁃induced MPE group was 14.28%（2/14），which was not significantly higher than that in OXC ⁃tolerant group or normal control group（P > 0.05 for both compari⁃ sons）. The rate of HLA ⁃B*1301 gene was 42.86% in OXC ⁃induced CARs group，which was significantly higher than that in OXC⁃tolerant group or normal control group（P < 0.05）. Conclusions HLA⁃B*1502 was probably associated with OXC induced SJS/TEN，whereas HLA⁃B*1301 was related to OXC⁃induced MPE.

Key words:

oxcarbazepine, MPE, SJS/TEN, HLA?B*1502, HLA?B*1301